-

Biological Dynamics to Participate in the Nephron Research Liquid Biopsy Innovation Symposium

Wednesday, June 16, 2021 at 12:10 p.m. ET / 9:10 a.m. PT

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a next-generation liquid biopsy company focused on detecting cancers at the earliest stages, will participate in the Nephron Research Liquid Biopsy Innovation Symposium.

CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Novel Approaches for Early Cancer Detection, on Wednesday, June 16, 2021, at 12:10 p.m. ET / 9:10 a.m. PT.

Biological Dynamics will discuss a transformative approach to cancer screening using a proprietary platform that enables the isolation and evaluation of non-DNA biomarkers, such as exosomes, exo-proteins, and surfaceomes. The company will also discuss how the access to these differentiated biomarkers from blood can empower cancer detection at the earliest stages.

About Biological Dynamics

Biological Dynamics, Inc. is a healthcare company committed to improving global health outcomes by detecting diseases at their earliest stages. The company's proprietary platform simplifies access to native-state biomarkers and nanoparticles, enabling differentiated multiomics applications. The company is applying its platform technology along with machine learning to detect cancers in blood. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.

Contacts

Investor Contact:
Kevin Han
Chief Financial Officer
kevin.han@biodyn.io

Industry:

Biological Dynamics, Inc.

Release Versions
English
Hashtags
#earlycancerdetection
#healthcare
#liquidbiopsy
#savelives

Contacts

Investor Contact:
Kevin Han
Chief Financial Officer
kevin.han@biodyn.io

Social Media Profiles
Biological Dynamics, Inc.
More News From Biological Dynamics, Inc.

Biological Dynamics launches ExoVita™ Pancreas and enrolls patients in ExoLuminate clinical trial

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a company commercializing its exosome-isolation ExoVerita™ platform for early disease surveillance and other applications, today announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory. Using blood-based exosome samples enriched on the proprietary ExoVerita instrument, the ExoVita Pancreas assay measures specific exosomal...

Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer research

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma (PDAC). The collaboration will test retrospective samples from over 200 patients starting this month. The ExoVerita™ platform is being investigated at NYU Langone Health, among other premier instituti...

Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif. Dr. Dhani’s PMWC showcase presentation on January 26th is part of the Clinical Utility of Liquid Biopsies track. The track focuses on how liquid biopsy technologies facilitate detection of early-stage canc...
Back to Newsroom